CD274 and melanoma: In a study of 40 patients with advanced melanoma undergoing pembrolizumab treatment, patients with detectable PD-L1-positive CTCs had a significantly longer PFS compared with PD-L1-negative patients, suggesting that PD-L1 expression on CTCs may predict response to pembrolizumab (Khattak et al., 2020).